Researchers have long focused on the STING (Stimulator of Interferon Genes) pathway as a way to harness the immune system’s natural defenses against cancer. This pathway, which plays a key role in helping the body defend against potential pathogens, can be leveraged to trigger an innate immune response that targets cancer cells. However, a study published in the journal Nature Chemical Biology, led by biochemist Lingyin Li, is spearheading a new school of thought.
Researchers reveal key differences in STING inhibition between humans and mice
